Tibet Rhodiola Pharmaceutical Holding Co (600211) - Total Liabilities
Based on the latest financial reports, Tibet Rhodiola Pharmaceutical Holding Co (600211) has total liabilities worth CN¥1.88 Billion CNY (≈ $274.45 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Tibet Rhodiola Pharmaceutical Holding Co cash flow conversion to assess how effectively this company generates cash.
Tibet Rhodiola Pharmaceutical Holding Co - Total Liabilities Trend (1996–2024)
This chart illustrates how Tibet Rhodiola Pharmaceutical Holding Co's total liabilities have evolved over time, based on quarterly financial data. Check Tibet Rhodiola Pharmaceutical Holding Co asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Tibet Rhodiola Pharmaceutical Holding Co Competitors by Total Liabilities
The table below lists competitors of Tibet Rhodiola Pharmaceutical Holding Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suzhou Nanomicro Technology Co Ltd
SHG:688690
|
China | CN¥309.13 Million |
|
NCC AB (publ)
ST:NCC-B
|
Sweden | Skr25.25 Billion |
|
Punjab & Sind Bank
NSE:PSB
|
India | Rs1.57 Trillion |
|
Aecon Group Inc.
TO:ARE
|
Canada | CA$2.82 Billion |
|
Syngene International Limited
NSE:SYNGENE
|
India | Rs18.07 Billion |
|
Stolt-Nielsen Limited
LSE:0OHK
|
UK | Nkr3.35 Billion |
|
ChipMOS Technologies
TW:8150
|
Taiwan | NT$21.34 Billion |
|
Coty Inc
NYSE:COTY
|
USA | $7.27 Billion |
Liability Composition Analysis (1996–2024)
This chart breaks down Tibet Rhodiola Pharmaceutical Holding Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Tibet Rhodiola Pharmaceutical Holding Co market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tibet Rhodiola Pharmaceutical Holding Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tibet Rhodiola Pharmaceutical Holding Co (1996–2024)
The table below shows the annual total liabilities of Tibet Rhodiola Pharmaceutical Holding Co from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥795.23 Million ≈ $116.37 Million |
-34.48% |
| 2023-12-31 | CN¥1.21 Billion ≈ $177.61 Million |
+13.58% |
| 2022-12-31 | CN¥1.07 Billion ≈ $156.38 Million |
-7.69% |
| 2021-12-31 | CN¥1.16 Billion ≈ $169.40 Million |
+225.26% |
| 2020-12-31 | CN¥355.91 Million ≈ $52.08 Million |
+11.07% |
| 2019-12-31 | CN¥320.44 Million ≈ $46.89 Million |
+16.57% |
| 2018-12-31 | CN¥274.89 Million ≈ $40.23 Million |
-3.42% |
| 2017-12-31 | CN¥284.64 Million ≈ $41.65 Million |
-82.56% |
| 2016-12-31 | CN¥1.63 Billion ≈ $238.88 Million |
+640.59% |
| 2015-12-31 | CN¥220.43 Million ≈ $32.26 Million |
-65.14% |
| 2014-12-31 | CN¥632.26 Million ≈ $92.52 Million |
-14.36% |
| 2013-12-31 | CN¥738.26 Million ≈ $108.03 Million |
+60.59% |
| 2012-12-31 | CN¥459.72 Million ≈ $67.27 Million |
+6.19% |
| 2011-12-31 | CN¥432.93 Million ≈ $63.35 Million |
+5.26% |
| 2010-12-31 | CN¥411.28 Million ≈ $60.18 Million |
-7.31% |
| 2009-12-31 | CN¥443.70 Million ≈ $64.93 Million |
-19.40% |
| 2008-12-31 | CN¥550.51 Million ≈ $80.56 Million |
-1.29% |
| 2007-12-31 | CN¥557.68 Million ≈ $81.61 Million |
+18.51% |
| 2006-12-31 | CN¥470.56 Million ≈ $68.86 Million |
+10.11% |
| 2005-12-31 | CN¥427.37 Million ≈ $62.54 Million |
+25.06% |
| 2004-12-31 | CN¥341.74 Million ≈ $50.01 Million |
+3.61% |
| 2003-12-31 | CN¥329.82 Million ≈ $48.26 Million |
+4.96% |
| 2002-12-31 | CN¥314.23 Million ≈ $45.98 Million |
+55.70% |
| 2001-12-31 | CN¥201.82 Million ≈ $29.53 Million |
+60.16% |
| 2000-12-31 | CN¥126.01 Million ≈ $18.44 Million |
+169.65% |
| 1999-12-31 | CN¥46.73 Million ≈ $6.84 Million |
-34.80% |
| 1998-12-31 | CN¥71.68 Million ≈ $10.49 Million |
+108.83% |
| 1997-12-31 | CN¥34.32 Million ≈ $5.02 Million |
+17.23% |
| 1996-12-31 | CN¥29.28 Million ≈ $4.28 Million |
-- |
About Tibet Rhodiola Pharmaceutical Holding Co
Tibet Rhodiola Pharmaceutical Holding Co. manufactures pharmaceuticals in China and internationally. The company offers biological products, Tibetan medicine, Chinese medicine, and chemical medicine products. It also provides capsules, biological preparations, granules, and film-coating agents for cardiovascular, cerebrovascular, hepatobiliary, sprains and contusions, rheumatism, rheumatoid arthr… Read more